| Title |
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, April 2014
|
| DOI | 10.1007/s10549-014-2947-1 |
| Pubmed ID | |
| Authors |
Masashi Ando, Hideko Yamauchi, Kenjiro Aogi, Satoru Shimizu, Hiroji Iwata, Norikazu Masuda, Naohito Yamamoto, Kenichi Inoue, Shinji Ohono, Katsumasa Kuroi, Tetsutaro Hamano, Tamie Sukigara, Yasuhiro Fujiwara |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 2% |
| Unknown | 99 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 12% |
| Other | 11 | 11% |
| Student > Ph. D. Student | 9 | 9% |
| Student > Doctoral Student | 9 | 9% |
| Student > Bachelor | 9 | 9% |
| Other | 25 | 25% |
| Unknown | 26 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 50% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Nursing and Health Professions | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 30 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2018.
All research outputs
#6,939,882
of 22,754,104 outputs
Outputs from Breast Cancer Research and Treatment
#1,513
of 4,652 outputs
Outputs of similar age
#67,293
of 226,853 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#22
of 67 outputs
Altmetric has tracked 22,754,104 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 4,652 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,853 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.